macular oedema secondary to retinal vein occlusion
Ophthalmology · 2012–2024
7decisions
3medicines
3carried consumer input
7individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| faricimab Treatment of macular oedema secondary to retinal vein occlusion (RVO), including branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). | Jul 2024 | Recommended | input received Macular Disease Foundation Australia |
| dexamethasone Macular oedema secondary to central or branch retinal vein occlusion in patients contraindicated to, unsuitable for, or who have failed prior treatment with… | Mar 2018 | Recommended with restriction | input received |
| ranibizumab Initial and continuing treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (both branch retinal vein occlusion and central… | Jul 2014 | Recommended with restriction | 7 individuals |
| ranibizumab Treatment of visual impairment due to diabetic macular oedema (DME) and macular oedema secondary to retinal vein occlusion (RVO). | Mar 2014 | Deferred | unclear |
| ranibizumab Treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch retinal vein occlusion and central retinal vein occlusion) in… | Nov 2013 | Deferred | no section in document |
| ranibizumab initial and continuing treatment by an ophthalmologist, of visual impairment due to macular oedema secondary to retinal vein occlusion | Nov 2012 | Recommended with restriction | no section in document |
| ranibizumab Initial and continuing treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch retinal vein occlusion and central… | Nov 2012 | Recommended with restriction | no section in document |
Who spoke
Macular Disease Foundation Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.